Francois Lebel - 21 Jun 2022 Form 4 Insider Report for SPECTRUM PHARMACEUTICALS INC

Role
Chief Medical Officer
Signature
/s/ Keith M. McGahan, attorney-in-fact for Francois Lebel
Issuer symbol
N/A
Transactions as of
21 Jun 2022
Net transactions value
-$10,507
Form type
4
Filing time
23 Jun 2022, 20:24:52 UTC
Previous filing
05 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPPI Common Stock, $0.001 par value Award $0 +405,040 +160% $0.000000 657,553 21 Jun 2022 Direct F1
transaction SPPI Common Stock, $0.001 par value Sale $4,913 -6,096 -0.93% $0.8060 651,457 22 Jun 2022 Direct F2
transaction SPPI Common Stock, $0.001 par value Sale $5,594 -6,667 -1% $0.8390 644,790 23 Jun 2022 Direct F2
holding SPPI Common Stock, $0.001 par value 7,226 21 Jun 2022 By 401(k) plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPPI Stock Option (Right to Buy) Award $0 +1,488,940 $0.000000 1,488,940 21 Jun 2022 Common Stock 1,488,940 $0.6300 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock unit grant was approved by Spectrum Pharmaceuticals, Inc.'s ("Spectrum") board of directors on January 27, 2022, subject to stockholder approval of the Amended and Restated 2018 Long-Term Incentive Plan (the "Plan") under which the restricted stock unit was granted. Spectrum's stockholders approved the Plan on June 21, 2022.
F2 All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer.
F3 The option grant was approved by Spectrum's board of directors on January 27, 2022, subject to stockholder approval of the Plan under which the option was granted. Spectrum's stockholders approved the Plan on June 21, 2022.
F4 One third of the aggregate amount of option shares shall vest on each of January 27, 2023, 2024 and 2025, respectively.